GeneNews Limited announced that it will release its Fourth Quarter and Full Year 2017 financial results before markets open on Tuesday, April 3, 2017.
TORONTO, April 2, 2018 /PRNewswire/ -- GeneNews Limited (“GeneNews” or the “Company”) (TSX:GEN) today announced that it will release its Fourth Quarter and Full Year 2017 financial results before markets open on Tuesday, April 3, 2017.
GeneNews’ Chairman and CEO, James R. Howard-Tripp, will host a conference call at 8:30 a.m. ET to review the financial results and discuss business developments during the period.
Fourth Quarter and Full Year 2017 Results Conference Call Details:
Date: April 3, 2018 Time: 8:30 a.m. ET Live Call: 1- 888-231-8191 (Canada and the United States) 1-647-427-7450 (International) Conference ID: 1781536 Replay: 1-855-859-2056 (Canada and the United States) 1-416-849-0833 (International) Password: 1781536
The call will also be broadcast live and archived on the Company’s website at www.GeneNews.com in the Investor’s section.
About GeneNews
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews’ common shares trade on the Toronto Stock Exchange under the symbol ‘GEN’. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
